For research use only
| Cat No. | ABC-TC0613 |
| Product Type | Human Lung Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Product Code | LU-65M; LU-65; LU65; Lu65; C-Lu-65; C-Lu65 |
Advance LU65 lung giant cell carcinoma line for cancer biology, RB gene expression analysis, and therapeutic testing in aggressive lung cancer.
LU65 is a human lung adenocarcinoma cell line derived from the lung tissue of a 64-year-old Japanese male patient with lung cancer. These adherent cells exhibit an epithelial-like morphology with polygonal shapes and grow as a monolayer in vitro, capable of continuous passaging. LU65 cells express typical epithelial markers such as cytokeratins and show genetic alterations commonly associated with lung adenocarcinoma, including mutations in oncogenes and tumor suppressor genes like EGFR and TP53. They demonstrate robust proliferative capacity and are used as a model to study lung cancer biology, tumor progression, and responses to targeted therapies. LU65 cells also provide valuable insights into mechanisms of chemoresistance and signaling pathways in lung adenocarcinoma research.
| Product Code | LU-65M; LU-65; LU65; Lu65; C-Lu-65; C-Lu65 |
| Species | Human |
| Cat.No | ABC-TC0613 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
LU65 cells serve as an NSCLC research model with lines like A549 and PC9 to study molecular mechanisms of cancer development and progression, including the role of KRAS and TP53 genes. They investigate drug resistance, particularly KRAS-mutant resistance to therapies like sotorasib, while exploring pathway interplay affecting drug response. These cells identify therapeutic targets through CRISPR-Cas9/drug screens, demonstrating that WEE1 inhibition enhances KRAS-targeted therapy efficacy. Additionally, LU65 enables studies on cell growth/proliferation/survival factors, immunohistochemistry for cellular characterization, and research on colony-stimulating factors in leukocytosis and prostaglandin production.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Amodio V, Yaeger R, Arcella P, et al. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discov. 2020;10(8):1129-1139. doi:10.1158/2159-8290.CD-20-0187
